Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan:13:100112.
doi: 10.1016/j.ahjo.2022.100112. Epub 2022 Mar 2.

Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and COVID-19-related outcomes: A patient-level analysis of the PCORnet blood pressure control lab

Steven M Smith  1   2 , Raj A Desai  2 , Marta G Walsh  1 , Ester Kim Nilles  3 , Katie Shaw  4 , Myra Smith  4 , Alanna M Chamberlain  5 , Catherine G Derington  6 , Adam P Bress  6 , Cynthia H Chuang  7 , Daniel E Ford  8 , Bradley W Taylor  9 , Sravani Chandaka  10 , Lav Parshottambhai Patel  10 , James McClay  11 , Elisa Priest  12 , Jyotsna Fuloria  13 , Kruti Doshi  14 , Faraz S Ahmad  15 , Anthony J Viera  16 , Madelaine Faulkner  17 , Emily C O'Brien  3 , Mark J Pletcher  17 , Rhonda M Cooper-DeHoff  1
Affiliations

Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and COVID-19-related outcomes: A patient-level analysis of the PCORnet blood pressure control lab

Steven M Smith et al. Am Heart J Plus. 2022 Jan.

Abstract

SARS-CoV-2 accesses host cells via angiotensin-converting enzyme-2, which is also affected by commonly used angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), raising concerns that ACEI or ARB exposure may portend differential COVID-19 outcomes. In parallel cohort studies of outpatient and inpatient COVID-19-diagnosed adults with hypertension, we assessed associations between antihypertensive exposure (ACEI/ARB vs. non-ACEI/ARB antihypertensives, as well as between ACEI- vs. ARB) at the time of COVID-19 diagnosis, using electronic health record data from PCORnet health systems. The primary outcomes were all-cause hospitalization or death (outpatient cohort) or all-cause death (inpatient), analyzed via Cox regression weighted by inverse probability of treatment weights. From February 2020 through December 9, 2020, 11,246 patients (3477 person-years) and 2200 patients (777 person-years) were included from 17 health systems in outpatient and inpatient cohorts, respectively. There were 1015 all-cause hospitalization or deaths in the outpatient cohort (incidence, 29.2 events per 100 person-years), with no significant difference by ACEI/ARB use (adjusted HR 1.01; 95% CI 0.88, 1.15). In the inpatient cohort, there were 218 all-cause deaths (incidence, 28.1 per 100 person-years) and ACEI/ARB exposure was associated with reduced death (adjusted HR, 0.76; 95% CI, 0.57, 0.99). ACEI, versus ARB exposure, was associated with higher risk of hospitalization in the outpatient cohort, but no difference in all-cause death in either cohort. There was no evidence of effect modification across pre-specified baseline characteristics. Our results suggest ACEI and ARB exposure have no detrimental effect on hospitalizations and may reduce death among hypertensive patients diagnosed with COVID-19.

Keywords: ACE inhibitors; ARBs; Covid-19; Hypertension; PCORnet.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Cumulative incidence of the primary outcomes in the outpatient (panels A and B) and inpatient (panels C and D) cohorts.
Fig. 2
Fig. 2
Stratified analyses of the primary outcome in the outpatient (panel A) and inpatient (panel B) cohorts.
See this image and copyright information in PMC

References

    1. Lan J., Ge J., Yu J., et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–220. doi: 10.1038/s41586-020-2180-5. - DOI - PubMed
    1. Hoffmann M., Kleine-Weber H., Schroeder S., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280. doi: 10.1016/j.cell.2020.02.052. e8. - DOI - PMC - PubMed
    1. Cohen J.B., Hanff T.C., William P., et al. Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir. Med. 2021;9(3):275–284. doi: 10.1016/S2213-2600(20)30558-0. - DOI - PMC - PubMed
    1. Lopes R.D., Macedo A.V.S., de Barros E., Silva P.G.M., et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19. JAMA. 2021;325(3):254. doi: 10.1001/jama.2020.25864. - DOI - PMC - PubMed
    1. Yu Wang H., Peng S., Ye Z., et al. Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension. Front. Med. 2021 doi: 10.1007/s11684-021-0850-9. Published online July 9. - DOI - PMC - PubMed